Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.

[1]  R. Trivedi,et al.  Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study , 2013, The clinical respiratory journal.

[2]  A. Woodcock,et al.  Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial , 2013, Thorax.

[3]  A. Woodcock,et al.  Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  A. Woodcock,et al.  Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma , 2012 .

[5]  N. Snowise,et al.  Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial. , 2012, Respiratory medicine.

[6]  A. Woodcock,et al.  Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. , 2012, Respiratory medicine.

[7]  A. Woodcock,et al.  24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids , 2012, European Respiratory Journal.

[8]  A. Woodcock,et al.  Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma , 2011, Respiratory research.

[9]  S. Levine,et al.  Achieving Symptom Control in Patients with Moderate Asthma , 2011, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

[10]  A. Woodcock,et al.  Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial , 2011, Respiratory research.

[11]  A. Woodcock,et al.  Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial , 2011, Thorax.

[12]  H. Friedman,et al.  Treatment with inhaled mometasone furoate reduces short-acting β(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  H. Friedman,et al.  Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma , 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

[14]  Mark Kosinski,et al.  The minimally important difference of the Asthma Control Test. , 2009, The Journal of allergy and clinical immunology.

[15]  M. Dubinsky,et al.  Effect of medication dosing frequency on adherence in chronic diseases. , 2009, The American journal of managed care.

[16]  I. McLay,et al.  X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. , 2008, Journal of medicinal chemistry.

[17]  S. Farrow,et al.  Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[18]  Reynold A Panettieri,et al.  Placebo response in asthma: a robust and objective phenomenon. , 2007, The Journal of allergy and clinical immunology.

[19]  E. Juniper,et al.  Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older , 2005, Health and quality of life outcomes.

[20]  J. Guest,et al.  Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. , 2005, Primary care respiratory journal : journal of the General Practice Airways Group.

[21]  P. Jones.  Interpreting thresholds for a clinically significant change in health status in asthma and COPD , 2002, European Respiratory Journal.

[22]  M. Kavuru,et al.  Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. , 2000, The Journal of allergy and clinical immunology.

[23]  W. Lumry,et al.  Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma , 2000 .

[24]  R. A. McIvor,et al.  The Placebo Effect in Asthma Drug Therapy Trials: A Meta-Analysis , 2000, The Journal of asthma : official journal of the Association for the Care of Asthma.

[25]  M. Aubier,et al.  Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. , 1999, Respiratory medicine.

[26]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[27]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[28]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[29]  W. Busse,et al.  Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial , 2012 .

[30]  J. Hankinson,et al.  Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. , 2010, Chest.

[31]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[32]  V. Pavlov,et al.  Diurnal variations in human pulmonary function. , 2008, International journal of clinical and experimental medicine.

[33]  W. Lumry,et al.  Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. , 2000, American journal of respiratory and critical care medicine.

[34]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.